Acrx stock forecast.

AcelRx Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ACRX updated stock price target summary.Oct 20, 2023 · ACRX stock had an impressive performance on October 20, 2023, with the potential for significant growth in the future. According to data from CNN Money, two analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.63, with a high estimate of 5.00 and a low estimate of 4.25. Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Marker Therapeutics Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The ...Wall Street expects a year-over-year increase in earnings on higher revenues when AcelRx Pharmaceuticals (ACRX) reports results for the quarter ended March 2023. While this widely-known consensus ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Evofem Biosciences Inc have a median target of 225.00, with a high estimate of 225.00 and a low estimate of 225.00.

3.91%. $84.57M. SRNEQ | Complete Sorrento Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.377.43. -0.11%. 9.38M. View today's AcelRx Pharmaceuticals Inc stock price and latest ACRX news and analysis. Create real-time notifications to follow any changes in the live stock price.

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. 12/31/2023. Next Earnings (Estimated) +423.4%. $-26,640,000.00.Forecast . Price target. 4.63 0.00 0.00%. The 2 analysts offering 1 year price forecasts for ACRX have a max estimate of — and a min estimate of —. Analyst rating. Based on 2 analysts giving stock ratings to ACRX in the past 3 months. EPS. Annual Annual Quarterly Quarterly More More

Future criteria checks 1/6. Acerinox is forecast to grow earnings and revenue by 14% and 1.9% per annum respectively. EPS is expected to grow by 14% per annum. Return on equity is forecast to be 11.2% in 3 years.Stock Price Forecast The 2 analysts offering 12-month price forecasts for Acurx Pharmaceuticals Inc have a median target of 11.50, with a high estimate of 13.00 and a low estimate of 10.00.Stock Price Forecast. The 12 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 31.00, with a high estimate of 31.26 and a low estimate of 19.00. The median ... Get a real-time Applied Digital Corporation (APLD) stock price quote with breaking news, financials, statistics, charts and more. Get a real ... the average rating for APLD stock is "Strong Buy." The 12-month stock price forecast is $14.21, which is an increase of 204.28% from the latest price. Price Target. $14.21 (204.28% upside ...

AcelRx Pharmaceuticals ( NASDAQ: ACRX) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue ...

ReTo Eco-Solutions, Inc., together with its subsidiaries, manufactures and distributes construction materials primarily in China. Its products include aggregates, bricks, pavers, and tiles. The company's construction materials are used for water absorption, flood control, and water retention; for gardens, roads, bridges, city squares, retaining ...

Stock Price Forecast. The 12 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 31.00, with a high estimate of 31.26 and a low estimate of 19.00. The median ... Analyst Forecast. According to 3 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price forecast is $29.67, which is an increase of 3.16% from the latest price.Baudax Bio Stock Forecast and Price Target. ... ACRX Stock Forecast: AcelRx Pharmaceuticals Buy 6 $0.69 Buy/Sell: $4.25 571.01% Baudax Bio Revenue Forecast for 2023 - 2025 - 2030. In the last two years, Baudax Bio's Revenue has grown, increasing from $490.00k to $1.27M – a growth of 159.18%.AcelRx Pharmaceuticals raised capital in December 2022, causing a roughly 50% dilution of existing shareholders on a fully diluted basis. Find out why ACRX stock is a Hold.May 15, 2023 · Earnings announcement* for ACRX: May 15, 2023. AcelRx Pharmaceuticals, Inc. is estimated to report earnings on 05/15/2023. The upcoming earnings date is derived from an algorithm based on a ... Oct 20, 2023 · ACRX stock had an impressive performance on October 20, 2023, with the potential for significant growth in the future. According to data from CNN Money, two analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 4.63, with a high estimate of 5.00 and a low estimate of 4.25. Heading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Find the latest AcelRx Pharmaceuticals, Inc. (ACRX) stock quote, history, news and other vital information to help you with your stock trading and investing.AcelRx Pharmaceuticals ( NASDAQ: ACRX) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue ...A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...AcelRx Pharmaceuticals last issued its earnings data on November 8th, 2023. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.21. The company earned $0.12 million during the quarter. AcelRx Pharmaceuticals has generated ($2.23) earnings per share over the last year ...The forecasts range from a low of $4.25 to a high of $5.00. The average price target represents an increase of 571.01% from the last closing price of $0.69. …3.91%. $84.57M. SRNEQ | Complete Sorrento Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

ACRX has an Altman Z-Score of -27.53 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for AcelRx Pharmaceuticals, Inc. (ACRX) stock, including valuation metrics, financial numbers, share information and more.The sales figure was up 433% sequentially, and the total revenue figure was up 133% year-over-year.Against this backdrop, several members of the Street believe ACRX’s $1.40 share price looks ...

ACRX Analyst Estimates Stock Screener Earnings Calendar Sectors Nasdaq | ACRX U.S.: Nasdaq AcelRx Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours …What this means: InvestorsObserver gives Acelrx Pharmaceutica (ACRX) an overall rank of 35, which is below average. Acelrx Pharmaceutica is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 35 means that 65% of stocks appear more favorable to our system.Currently 8 wall-street analysts regularly analyze the financials of Acelrx Pharmaceuticals, Inc. on a frequent basis to provide recommendations along with target share price. 8 analysts offering 12-month price forecasts for Acelrx Pharmaceuticals, Inc. (ACRX) have a share price target of $4.63.Nov 22, 2023 · ACRX has an Altman Z-Score of -27.53 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for AcelRx Pharmaceuticals, Inc. (ACRX) stock, including valuation metrics, financial numbers, share information and more. Find the latest VYNE Therapeutics Inc. (VYNE) stock quote, history, news and other vital information to help you with your stock trading and investing.Average. 4.63. Current Price. $0.50. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading ... Baudax Bio Stock Forecast and Price Target. ... ACRX Stock Forecast: AcelRx Pharmaceuticals Buy 6 $0.69 Buy/Sell: $4.25 571.01% Baudax Bio Revenue Forecast for 2023 - 2025 - 2030. In the last two years, Baudax Bio's Revenue has grown, increasing from $490.00k to $1.27M – a growth of 159.18%.

ACU one year forecast. Acme United stock monthly and weekly forecasts. Skip to content. FORECST.COM 2023 – 2026 Stock Market Forecast ACU stock forecast for 2023 – 2027. Last updated: September 22, 2023. Are you interested in Acme United Corporation stocks prediction? ... ACRX Stock Forecast; ACRS Stock Forecast;

View the latest AcelRx Pharmaceuticals Inc. (ACRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Don't miss ACRX stock next rating changes... Join Now | Login. Need Help? Call 1­-866-­796-­7386 Home; Stock Screener; Stock Ratings; Stock Portfolios; Pricing; Help; About Us « back to stock screener ACRX stock: AcelRx Pharmaceuticals Inc Current Rating. Sell. Previous Rating. Sell. Our Strong Buys double the S&P500! Learn more.AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE ...AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Find the latest AcelRx Pharmaceuticals, Inc. (ACRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Price Forecast. The 12 analysts offering 12-month price forecasts for ImmunoGen Inc have a median target of 31.00, with a high estimate of 31.26 and a low estimate of 19.00. The median ... Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Corbus Pharmaceuticals Holdings Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00.View the latest AcelRx Pharmaceuticals Inc. (ACRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Marker Therapeutics Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The ...Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Corbus Pharmaceuticals Holdings Inc have a median target of 20.00, with a high estimate of 20.00 and a low estimate of 20.00.12.98%. Get the latest AcelRx Pharmaceuticals Inc (ACRX) real-time quote, historical performance, charts, and other financial information to help you make more informed …Here are three reasons Aurora Cannabis stock may finally be a buy. Image source: Getty Images. 1. Cost-cutting and restructuring. Aurora Cannabis has been implementing a comprehensive plan to ...When planning outdoor activities or making travel arrangements, having access to accurate weather forecasts is crucial. One commonly used tool is the 7 day weather forecast, which provides an outlook for the upcoming week.

Acurx Pharmaceuticals, Inc. Analyst Report: Pfizer Inc. Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...About CohBar Stock (NASDAQ:CWBR) CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; …Instagram:https://instagram. home building stockswebull virtual tradingspdw stocketfs with monthly dividend payments Based on 4 Wall Street analysts offering 12 month price targets for Tempest Therapeutics in the last 3 months. The average price target is $21.67 with a high forecast of $47.00 and a low forecast of $8.00. The average price target represents a 452.81% change from the last price of $3.92. Highest Price Target $47.00. Average Price Target $21.67. Find real-time CTMX - CytomX Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. groundfloor investing reviewscharles schwab or fidelity May 15, 2023 · Earnings announcement* for ACRX: May 15, 2023. AcelRx Pharmaceuticals, Inc. is estimated to report earnings on 05/15/2023. The upcoming earnings date is derived from an algorithm based on a ... liberty media corp AcelRx Pharmaceuticals ( NASDAQ: ACRX) is scheduled to announce Q1 earnings results on Wednesday, May 10th, after market close. The consensus EPS Estimate is -$0.80 and the consensus Revenue ...AcelRx Pharmaceuticals Inc AcelRx Pharmaceuticals Inc ACRX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...AcelRx Pharmaceuticals (NASDAQ:ACRX) dropped ~15% aftermarket as the firm will effect a 1-for-20 reverse stock split on Tuesday at 5.01 pm ET.The company's stock will begin trading on a split ...